Variables | Subgroups | Number of studies | Sensitivity (95% CI) | Specificity (95% CI) | Positive LR (95% CI) | Negative LR (95% CI) | Diagnostic odds ratio (95% CI) | Coeff. | SE | P value | RDOR (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|
RRT rate | < 20% | 2 | 0.80 (0.57–0.92) | 0.82 (0.73–0.88) | 4.35 (2.66–7.10) | 0.25 (0.11–0.61) | 17.52 (5.16–59.44) | 0.17 | 0.59 | 0.77 | 1.19 (0.37–3.78) |
≥ 20% | 4 | 0.85 (0.69–0.93) | 0.76 (0.54–0.89) | 2.64 (1.62–4.32) | 0.25 (0.12–0.51) | 12.81 (4.19–39.12) | |||||
Follow-up duration | Not reported or < 7 days | 3 | 0.80 (0.74–0.8 5) | 0.74 (0.52–0.89) | 2.89 (1.49–5.57) | 0.37 (0.28–0.50) | 4.97 (3.32–7.44) | 1.31 | 0.78 | 0.09 | 3.71 (0.80–71.11) |
≥ 7 days | 3 | 0.91 (0.66–0.98) | 0.77 (0.65–0.86) | 3.42 (2.41–4.86) | 0.15 (0.07–0.34) | 30.46 (13.13–70.66) | |||||
AKI stage enrolled | Stage 3 | 1 |  |  |  |  |  | 1.75 | 0.43 | < 0.01 | 5.75 (2.51–13.33) |
Stage 1 or 2 | 5 | 0.85 (0.68–0.94) | 0.80 (0.73–0.86) | 3.77 (2.80–5.09) | 0.21 (0.11–0.41) | 24.93 (12.45–49.91) |